110 studies found for:    MUC1
Show Display Options
Rank Status Study
1 Active, not recruiting A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
Condition: Prostate Cancer
Intervention: Biological: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
2 Completed
Has Results
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Condition: Risk for Colorectal Cancer
Intervention: Biological: MUC1 - Poly ICLC
3 Completed A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
Condition: Multiple Myeloma
Intervention: Biological: ImMucin, hGM-CSF
4 Recruiting Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
Conditions: Colorectal Adenoma;   Colorectal Adenoma With Severe Dysplasia;   Colorectal Tubulovillous Adenoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: MUC1 Peptide-Poly-ICLC Vaccine;   Other: Placebo;   Other: Quality-of-Life Assessment
5 Withdrawn A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Conditions: Multiple Myeloma;   Tumors
Intervention: Biological: Peptide Vaccine (MUC-1)
6 Suspended Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: Vaccine + PolyICLC
7 Active, not recruiting MUC1 Vaccine for Triple-negative Breast Cancer
Conditions: Breast Cancer;   Inflammatory Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine;   Biological: poly ICLC;   Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry
8 Active, not recruiting MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: MUC_1
9 Terminated Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: recombinant vaccinia-MUC1 vaccine;   Biological: recombinant vaccinia-TRICOM vaccine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
10 Recruiting Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers
Condition: Epithelial Cancers of the Lung, Breast, Ovary, Prostate and Colon
Intervention: Drug: Ad-sig-hMUC-1/ecdCD40L vector vaccine
11 Terminated Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Biological: MVA-MUC1-IL2
12 Completed Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: MVA-MUC1-IL2;   Drug: 1st line Chemotherapy
13 Recruiting Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients
Conditions: Cystic Fibrosis;   Dietary Modification
Interventions: Other: polyunsaturated fatty acids n-3;   Other: placebo
14 Withdrawn Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC) Stage III
Interventions: Other: Biological: MUC1 peptide specific immunotherapy;   Drug: Cyclophosphamide (CPA)
15 Completed Vaccine Therapy in Treating Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Biological: MUC1-KLH vaccine/QS21
16 Recruiting A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, in Relapse;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: GO-203-2c
17 Completed Ovarian Cancer Vaccine for Patients in Remission
Condition: Epithelial Ovarian Cancer
Intervention: Biological: MUC1 Dendritic Cell Vaccine (Cvac)
18 Active, not recruiting Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Biological: CpG oligodeoxynucleotide;   Biological: HER-2/neu peptide vaccine;   Biological: MUC-1 peptide vaccine;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Other: immunoenzyme technique;   Other: immunologic technique
19 Recruiting Mucin Glycosylating Enzymes in Head and Neck Cancers
Condition: Mucin Glycosylating Enzyme, HNSCC
20 Completed Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: MUC1-KLH vaccine/QS21

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years